Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Pharma Mar S.A.
PHMPharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain. Address: Avenida de los Reyes, 1, Madrid, Spain, 28770
Analytics
Objectif de Cours de WallStreet
72.4 EURRatio C/B
1931.25Rendement du dividende
0.89 %Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés PHM
Analyse des dividendes PHM
Croissance des dividendes sur 5 ans
–Croissance continue
1 annéeRatio de distribution Moyenne sur 5 ans
25 %Historique des dividendes PHM
Valorisation des titres PHM
financières PHM
Résultats | 2019 | Dynamique |